Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices

U.S. Representatives Peter Welch and Francis Rooney are urging the Federal Trade Commission and Department of Justice to take a close look at Bristol-Myers' $74 billion purchase of Celgene. Why? Past pharma mergers have spawned price hikes that hurt consumers, the Congressmen say.